Antihyperglycemic Coverage by RAMQ Class Biguanides Glucosidase Inhibitors
Antihyperglycemic Coverage by RAMQ Class Biguanides α-Glucosidase Inhibitors Medication $/day MONO at if SU and max MET dose NT or CI Metformin (Glucophage) 0. 18 Acarbose (Glucobay) 1. 03 Alogliptin (Nesina) 2. 10 EN 167 Linagliptin (Trajenta) 2. 25 EN 167 Saxagliptin (Onglyza) 2. 30 Sitagliptin (Januvia) 2. 62 EN 167 Canagliflozin (Invokana) 2. 62 EN 167 Dapagliflozin (Forxiga) 2. 45 Empagliflozin (Jardiance) 2. 62 Liraglutide (Victoza) Exenatide (Byetta) Exenatide QW (Bydureon) GLP-1 R Agonists Dulaglutide (Trulicity) Semaglutide (Ozempic) 6. 85 2. 49 6. 85 DPP-4 Inhibitors SGLT 2 Inhibitors Thiazolidinediones Insulin Secretagogues EN 167 + MET if SU CI, NT or INEFF EN 148 (EN 150 Kazano) EN 148 (EN 150 Jentaduetto) EN 148 (EN 150 Komboglyze) EN 148 (EN 150 Janumet et XR) EN 148 (EN 199 Xigduo) EN 148 (EN 199 Synjardy) + MET + SU IF if DPP 4 i if Met CVD INEFF, NT or CI, NT + BMICI> and or 30 and INEFF A 1 c>7 high A 1 c If other SU NT or INEFF EN 149 EN 179 Form Pioglitazone (Actos) 1. 05 EN 121 EN 118 EN 119 Rosiglitazone (Avandia) 2. 87 EN 121 EN 119 Gliclazide (Diamicron) Glimepiride ( Amaryl) Glyburide (Diabeta) Repaglinide (Gluco. Norm) 0. 50 0. 77 0. 23 0. 84 EN 118 (EN 81 Avandamet) EN 23 Green = on general list: no code or form required Orange = Médicament d’exception: code or form required NT=Not tolerated INEFF=Inefficacious CI=Contraindicated SU=Sulfonylurea MET=Metformin Mono=Monotherapy Form=Médicament d’exception form required EN 199 requires 3 month stability of each component x 3 months JF Yale october 2018
- Slides: 1